person · Reporting owner
Carter Paul Rutherford
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP Commercial Ops | August 01, 2016 | August 03, 2016 |
| Immatics N.V.IMTX · Entity 4718 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date August 01, 2016 · Filed August 03, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,305 |
Ending reported balance
After 2016-08-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2016-08-01 · Exercise / conversion · Acquired 1,817 · Balance 64,122 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 2 · 2016-08-01 · Exercise / conversion · Acquired 183 · Balance 64,305 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 3 · 2016-08-01 · Sale · Disposed 2,000 · Balance 62,305 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.56 · Expires 2023-02-01 | Direct | 4,803 |
Reported balance
After 2016-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-08-01 · Exercise / conversion · Disposed 1,817 · Balance 4,803 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.91 · Expires 2019-07-29 | Direct | 26,043 |
Reported balance
After 2016-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-08-01 · Exercise / conversion · Disposed 183 · Balance 26,043 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Immatics N.V.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.09 · Expires 2036-06-15 | Direct | 48,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 48,000 · Balance 48,000 F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALDER BIOPHARMACEUTICALS INC
Report date October 22, 2019 · Filed October 24, 2019
Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.10 · Expires 2025-09-27 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F2: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of September 28, 2015, the vesting commencement date, one-third of the shares underlying the option on the two-year anniversary of the vesting commencement date and one-third of the shares underlying the option on the three-year anniversary of the vesting commencement date, for so long as the recipient of the option provides continuous service to the issuer, such that the total shares shall be fully vested on the three-year anniversary of the vesting commencement date. The shares subject to this option are fully vested as of the date hereof. F3: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.26 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F3: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. F4: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.90 · Expires 2027-05-23 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2028-05-22 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.01 · Expires 2029-05-22 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-22 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.
F2: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of September 28, 2015, the vesting commencement date, one-third of the shares underlying the option on the two-year anniversary of the vesting commencement date and one-third of the shares underlying the option on the three-year anniversary of the vesting commencement date, for so long as the recipient of the option provides continuous service to the issuer, such that the total shares shall be fully vested on the three-year anniversary of the vesting commencement date. The shares subject to this option are fully vested as of the date hereof.
F3: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor.
F4: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F5: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
F7: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F8: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 1
1 source rowRow 1 · 2022-06-16 · Disposition to issuer · Disposed 20,320 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code.
F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy.
F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:44 UTC | Immatics N.V. IMTX · Entity 4718 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000950103-26-009242 · ownership.xml · derivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2036-06-15 F1 · derivative.exercise_date: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:15 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerOrdinary Shares | 20,320 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023432 · doc4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:20 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 9,117 | $2.96 | $26,986.32 |
DisclosureSEC source: 0000950138-20-000257 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,320 Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:55 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001209191-19-053911 · doc4.xml · derivative · entry 5 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2029-05-22 F1 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:55 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001209191-19-053911 · doc4.xml · derivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F1 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:55 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001209191-19-053911 · doc4.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-05-23 F1 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F6 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:55 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $29.26 | $0.00 |
DisclosureSEC source: 0001209191-19-053911 · doc4.xml · derivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-25 F1 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F3 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:55 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $31.10 | $0.00 |
DisclosureSEC source: 0001209191-19-053911 · doc4.xml · derivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2025-09-27 F1 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of September 28, 2015, the vesting commencement date, one-third of the shares underlying the option on the two-year anniversary of the vesting commencement date and one-third of the shares underlying the option on the three-year anniversary of the vesting commencement date, for so long as the recipient of the option provides continuous service to the issuer, such that the total shares shall be fully vested on the three-year anniversary of the vesting commencement date. The shares subject to this option are fully vested as of the date hereof. F3 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. Read SEC document |
| May 23, 2019 Filed May 28, 2019 18:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001209191-19-033071 · doc4.xml · derivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-05-22 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 10:53 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 19,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000308 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,437 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| May 15, 2019 Filed May 17, 2019 10:53 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 8,906 | $15.21 | $135,460.26 |
DisclosureSEC source: 0000950138-19-000308 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,041 Read SEC document |
| May 23, 2018 Filed May 25, 2018 17:23 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001209191-18-033607 · doc4.xml · derivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:32 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 18,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000421 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,947 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| May 24, 2017 Filed May 26, 2017 17:47 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001209191-17-035976 · doc4.xml · derivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| August 01, 2016 Filed Aug 3, 2016 20:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 183 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-16-059414 · form4.xml · derivative · entry 5 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,043 Underlying: Common Stock · 183 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 01, 2016 Filed Aug 3, 2016 20:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,817 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-16-059414 · form4.xml · derivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,803 Underlying: Common Stock · 1,817 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| August 01, 2016 Filed Aug 3, 2016 20:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $79.81 | $159,620.00 |
DisclosureSEC source: 0001127602-16-059414 · form4.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,305 Read SEC document |
| August 01, 2016 Filed Aug 3, 2016 20:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 183 | $24.91 | $4,557.62 |
DisclosureSEC source: 0001127602-16-059414 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2016 Filed Aug 3, 2016 20:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,817 | $40.56 | $73,697.52 |
DisclosureSEC source: 0001127602-16-059414 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 31, 2016 Filed Aug 2, 2016 20:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-059283 · form4.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest 25% annually over a four year period after the date of grant. F2 · derivative.expiration_date: The restricted stock units vest 25% annually over a four year period after the date of grant. Read SEC document |
| July 31, 2016 Filed Aug 2, 2016 20:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,317 | $79.47 | $104,661.99 |
DisclosureSEC source: 0001127602-16-059283 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,305 Read SEC document |
| July 31, 2016 Filed Aug 2, 2016 20:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-059283 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 17:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-16-057490 · form4.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,226 Underlying: Common Stock · 2,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 17:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $83.12 | $166,249.60 |
DisclosureSEC source: 0001127602-16-057490 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,122 F3 · price: Sale prices reported for the transactions reported here range from $83.02 to $83.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 17:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,000 | $24.91 | $49,810.00 |
DisclosureSEC source: 0001127602-16-057490 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 20:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-16-054725 · form4.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,226 Underlying: Common Stock · 2,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 20:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $87.02 | $174,040.20 |
DisclosureSEC source: 0001127602-16-054725 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,122 F3 · price: Sale prices reported for the transactions reported here range from $87.0101 to $87.03. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 20:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,000 | $24.91 | $49,810.00 |
DisclosureSEC source: 0001127602-16-054725 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 3,865 | $0.00 Strike: $80.65 | $0.00 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · derivative · entry 9 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,906 Underlying: Common Stock · 3,865 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,795 | $0.00 Strike: $80.65 | $0.00 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · derivative · entry 8 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,795 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,232 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · derivative · entry 7 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,226 Underlying: Common Stock · 4,232 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 43,200 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · derivative · entry 6 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,200 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 57,092 | $86.85 | $4,958,600.06 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · nonDerivative · entry 5 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,122 F4 · price: Sale prices reported for the transactions reported here range from $86.6075 to $87.1008. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,865 | $80.65 | $311,712.25 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · nonDerivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,795 | $80.65 | $467,366.75 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,232 | $24.91 | $105,397.96 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 31, 2016 Filed Jun 2, 2016 20:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 43,200 | $24.30 | $1,049,544.00 |
DisclosureSEC source: 0001127602-16-054483 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 02, 2016 Filed May 4, 2016 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 183 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-16-051112 · form4.xml · derivative · entry 5 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,458 Underlying: Common Stock · 183 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 02, 2016 Filed May 4, 2016 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,817 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-16-051112 · form4.xml · derivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,620 Underlying: Common Stock · 1,817 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 02, 2016 Filed May 4, 2016 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $88.72 | $177,447.80 |
DisclosureSEC source: 0001127602-16-051112 · form4.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,122 F4 · price: Sale prices reported for the transactions reported here range from $88.715 to $88.765. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 02, 2016 Filed May 4, 2016 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 183 | $24.91 | $4,557.62 |
DisclosureSEC source: 0001127602-16-051112 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 02, 2016 Filed May 4, 2016 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,817 | $40.56 | $73,697.52 |
DisclosureSEC source: 0001127602-16-051112 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 01, 2016 Filed Apr 5, 2016 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-16-048891 · form4.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,641 Underlying: Common Stock · 2,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| April 01, 2016 Filed Apr 5, 2016 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $91.34 | $182,680.00 |
DisclosureSEC source: 0001127602-16-048891 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,122 Read SEC document |
| April 01, 2016 Filed Apr 5, 2016 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,000 | $24.91 | $49,810.00 |
DisclosureSEC source: 0001127602-16-048891 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-16-044760 · form4.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,641 Underlying: Common Stock · 2,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $87.90 | $175,800.00 |
DisclosureSEC source: 0001127602-16-044760 · form4.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,122 Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,000 | $24.91 | $49,810.00 |
DisclosureSEC source: 0001127602-16-044760 · form4.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 7,395 | $91.15 | $674,054.25 |
DisclosureSEC source: 0001127602-16-042271 · form4.xml · nonDerivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,122 Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 9,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-042271 · form4.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,517 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2013. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.